Significance of the rs754635 variant of the cholecystokinin gene in the development of obesity in children

Authors

DOI:

https://doi.org/10.15574/SP.2023.133.17

Keywords:

cholecystokinin, analysis of single nucleotide gene variants, children, metabolically unhealthy obesity, metabolically healthy obesity

Abstract

So far, the possible influence of single nucleotide variants (SNV) of the cholecystokinin (CCK) gene on the likelihood of developing obesity and metabolic disorders in children has not been demonstrated.

The aim of the study SNV associations of the CSK gene to predict the probability of obesity and personalize the development trajectory of various metabolic disorders associated with obesity in children.

Materials and methods. 252 obese children aged 6-18 years were examined. The main group (n=152) was represented by children with metabolically unhealthy obesity (MUO). The control group (n=100) consolidated of children with metabolically healthy obesity (MHO). Whole genome sequencing (CeGat, Germany) was performed in 31 children of the main and 21 children of the control group. Serum levels of interleukin-1β were measured using a chemiluminescent immunoassay (CLIA) method, interleukin-6 - by enzyme-linked immunosorbent assay (ELISA), Synevo, Ukraine.

Results. The G allele of SNV rs754635 of the CCK gene was significantly more frequent among children with both MHO (t=10.93; p<0.05) and MUO (t=12.96; p<0.05) compared to healthy individuals. The G allele of SNV rs754635 of the CCK gene was associated with basal hyperglycemia (r=0.44) and impaired carbohydrate tolerance (r=0.33) in the MHO phenotype and with the atherogenicity index of the lipid spectrum (r=0.40) and was inversely correlated with the level of high-density lipoproteins (HDL) (r=-0.58) in children with MUO phenotype, p<0.05.

Conclusions. The G allele SNV rs754635 of the CCK gene is associated with obesity and the development of metabolic disorders.

The research was carried out in accordance with the principles of the Declaration of Helsinki. The research protocol was approved by the Local Ethics Committee of the institution mentioned in the work. Informed consent of parents or their guardians was obtained for conducting research.

No conflict of interests was declared by the author.

References

Abaturov A, Nikulina A. (2019). Genotype C/C 13910 of the Lactase Gene as a Risk Factor for the Formation of Insulin-Resistant Obesity in Children. Acta Medica (Hradec Kralove). 62 (4): 150-155. https://doi.org/10.14712/18059694.2020.4; PMid:32036847

Abaturov A, Nikulina A. (2021). Obesity in Children with Leptin Receptor Gene Polymorphisms. Acta Medica (Hradec Kralove). 64 (3): 158-164. https://doi.org/10.14712/18059694.2021.27; PMid:34779381

Alberti KG, Zimmet P, Kaufman F et al. (2007). The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes. 8 (5): 299-306. https://doi.org/10.1111/j.1399-5448.2007.00271.x; PMid:17850473

Breen DM, Yue JT, Rasmussen BA et al. (2011, Dec). Duodenal PKC-δ and cholecystokinin signaling axis regulates glucose production. Diabetes. 60 (12): 3148-3153. https://doi.org/10.2337/db11-0852; PMid:21984583 PMCid:PMC3219935

Cawthon CR, de La Serre CB. (2021, Apr). The critical role of CCK in the regulation of food intake and diet-induced obesity. Peptides. 138: 170492. https://doi.org/10.1016/j.peptides.2020.170492; PMid:33422646

Chauhan W, Fatma R, Wahab A et al. (2022). Cataloging the potential SNPs (single nucleotide polymorphisms) associated with quantitative traits, viz. BMI (body mass index), IQ (intelligence quotient) and BP (blood pressure): an updated review. Egyptian J Med Hum Gen. 23: 57. https://doi.org/10.1186/s43042-022-00266-0

Cheung GW, Kokorovic A, Lam CK et al. (2009, Aug). Intestinal cholecystokinin controls glucose production through a neuronal network. Cell Metab. 10 (2): 99-109. https://doi.org/10.1016/j.cmet.2009.07.005; PMid:19656488

Deelen P, Bonder MJ, van der Velde KJ et al. (2014). Genotype harmonizer: automatic strand alignment and format conversion for genotype data integration. BMC Res Notes. 7: 901. https://doi.org/10.1186/1756-0500-7-901; PMid:25495213 PMCid:PMC4307387

Deignan JL, Chung WK, Kearney HM et al. (2019). Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 21 (6): 1267-1270. https://doi.org/10.1038/s41436-019-0478-1; PMid:31015575 PMCid:PMC6559819

Demenis C, McLaughlin J, Smith CP. (2017, Sep 1). Sulfated Cholecystokinin-8 Promotes CD36-Mediated Fatty Acid Uptake into Primary Mouse Duodenal Enterocytes. Front Physiol. 8: 660. https://doi.org/10.3389/fphys.2017.00660; PMid:28919867 PMCid:PMC5586203

Desai AJ, Dong M, Langlais BT et al. (2017, Aug). Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype. Am J Clin Nutr. 106 (2): 447-456. https://doi.org/10.3945/ajcn.117.156943; PMid:28592602 PMCid:PMC5525122

Draznin B, Aroda VR, Bakris G et al. (2022). American Diabetes Association Professional Practice Committee. 6. Glycemic targets: Standards of Medical Care in Diabetes - 2022. Diabetes Care. 45 (1): 83-96. https://doi.org/10.2337/dc22-S006; PMid:34964868

Elkins C, Fruh Sh, Jones L et al. (2019). Clinical Practice Recommendations for Pediatric Dyslipidemia. Journal of Pediatric Health Care. 33 (4): 494-504. https://doi.org/10.1016/j.pedhc.2019.02.009; PMid:31227123

Flynn JT, Kaelber DC, Baker-Smith CM et al. (2017, Sep). Subcommittee on screening and management of high blood pressure in children. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 140 (3): e20171904. https://doi.org/10.1542/peds.2017-1904; PMid:28827377

Gibbs J, Young RC, Smith GP. (1973, Oct 12). Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature. 245 (5424): 323-325. https://doi.org/10.1038/245323a0; PMid:4586439

Graff M, Scott RA, Justice AE et al. (2017). Genome-wide physical activity interactions in adiposity - A meta-analysis of 200,452 adults [published correction appears in PLoS Genet. 2017 Aug 23; 13 (8): e1006972]. PLoS Genet. 13 (4): e1006528.

Gunning AC, Fryer V, Fasham J et al. (2021, Aug). Assessing performance of pathogenicity predictors using clinically relevant variant datasets. J Med Genet. 58 (8): 547-555. https://doi.org/10.1136/jmedgenet-2020-107003; PMid:32843488 PMCid:PMC8327323

Hongshan J, Rong L, Shou-Wei D et al. (2014). Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. In BMC Bioinformatics. 15: 182. https://doi.org/10.1186/1471-2105-15-182; PMid:24925680 PMCid:PMC4074385

Ivy AC, Oldberg E. (1928). Hormone mechanism for gallbladder contraction and evacuation. Am J Physiol. 86: 599-613. https://doi.org/10.1152/ajplegacy.1928.86.3.599

Kim HT, Desouza AH, Umhoefer H et al. (2022, May). Cholecystokinin attenuates β-cell apoptosis in both mouse and human islets. Transl Res. 243: 1-13. https://doi.org/10.1016/j.trsl.2021.10.005; PMid:34740874 PMCid:PMC9504967

King A, Yang Q, Huesman S et al. (2015, Nov 1). Lipid transport in cholecystokinin knockout mice. Physiol Behav. 151: 198-206. https://doi.org/10.1016/j.physbeh.2015.07.009; PMid:26171590 PMCid:PMC4587287

Koefoed P, Woldbye DP, Hansen TO et al. (2010, Apr). Gene variations in the cholecystokinin system in patients with panic disorder. Psychiatr Genet. 20 (2): 59-64. https://doi.org/10.1097/YPG.0b013e32833511a8; PMid:20023595

Kuntz E, Pinget M, Damgé P. (2004, Nov 10). Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats. JOP. 5 (6): 464-475. PMID: 15536283.

Lavine JA, Kibbe CR, Baan M et al. (2015, Nov 15). Cholecystokinin expression in the β-cell leads to increased β-cell area in aged mice and protects from streptozotocin-induced diabetes and apoptosis. Am J Physiol Endocrinol Metab. 309 (10): E819-28. https://doi.org/10.1152/ajpendo.00159.2015; PMid:26394663 PMCid:PMC4652070

Li H, Durbin R. (2009). Fast and accurate short read alignment with Burrows‐Wheeler transform. Bioinformatics. 25 (14): 1754-1760. https://doi.org/10.1093/bioinformatics/btp324; PMid:19451168 PMCid:PMC2705234

Little J, Higgins JP, Ioannidis JP et al. (2009, Nov). STrengthening the REporting of Genetic Association Studies. STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement. Genet Epidemiol. 33 (7): 581-598. https://doi.org/10.1002/gepi.20410; PMid:19278015

Livesey BJ, Marsh JA. (2020, Jul). Using deep mutational scanning to benchmark variant effect predictors and identify disease mutations. Mol Syst Biol. 16 (7): e9380. https://doi.org/10.15252/msb.20199380; PMid:32627955 PMCid:PMC7336272

Mahmood K, Jung CH, Philip G et al. (2017, May 16). Variant effect prediction tools assessed using independent, functional assay-based datasets: implications for discovery and diagnostics. Hum Genomics. 11 (1): 10. https://doi.org/10.1186/s40246-017-0104-8; PMid:28511696 PMCid:PMC5433009

Mesgari-Abbasi M, Abbasalizad Farhangi M. (2020, Jan-Mar). Serum concentrations of cholecystokinin, peptide YY, ghrelin and high sensitive C-reactive protein in association with metabolic syndrome ingredients in obese individuals. Acta Endocrinol (Buchar). 16 (1): 37-42. https://doi.org/10.4183/aeb.2020.37; PMid:32685036 PMCid:PMC7363996

Miller LJ, Harikumar KG, Wootten D et al. (2021, Jun 2). Roles of Cholecystokinin in the Nutritional Continuum. Physiology and Potential Therapeutics. Front Endocrinol (Lausanne). 12: 684656. https://doi.org/10.3389/fendo.2021.684656; PMid:34149622 PMCid:PMC8206557

Miyasaka K, Takiguchi S, Funakoshi A. (2007). Cholecystokinin 1A receptor polymorphisms. Curr Top Med Chem. 7 (12): 1205-1210. https://doi.org/10.2174/156802607780960465; PMid:17584142

Mose LE, Wilkerson MD, Hayes DN et al. (2014). ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics. 30 (19): 2813-2815. https://doi.org/10.1093/bioinformatics/btu376; PMid:24907369 PMCid:PMC4173014

Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. (2007). The WHO reference for children aged 5-19 years is: de Onis M, Onyango A.W., Borghi E., Siyam A., Nishida C., Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bulletin of the World Health Organization. 85: 660-667. URL: http://www.who.int/growthref/growthref_who_bull/en/index.html. Accessed 18 May 2023. https://doi.org/10.2471/BLT.07.043497; PMid:18026621 PMCid:PMC2636412

Pathak V, Flatt PR, Irwin N. (2018, Feb). Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes. Peptides. 100: 229-235. https://doi.org/10.1016/j.peptides.2017.09.007; PMid:29412823

Peplies J, Börnhorst C, Günther K et al. (2016, Sep 2). IDEFICS consortium. Longitudinal associations of lifestyle factors and weight status with insulin resistance (HOMA-IR) in preadolescent children: the large prospective cohort study IDEFICS. Int J Behav Nutr Phys Act. 13 (1): 97. https://doi.org/10.1186/s12966-016-0424-4; PMid:27590045 PMCid:PMC5009569

Phung HM, Jang D, Trinh TA et al. (2022, Jul). Regulation of appetite-related neuropeptides by Panax ginseng: A novel approach for obesity treatment. J Ginseng Res. 46 (4): 609-619. https://doi.org/10.1016/j.jgr.2022.03.007; PMid:35818423 PMCid:PMC9270656

Plaza A, Merino B, Cano V et al. (2018, Mar). Cholecystokinin is involved in triglyceride fatty acid uptake by rat adipose tissue. J Endocrinol. 236 (3): 137-150. https://doi.org/10.1530/JOE-17-0580; PMid:29339381

RefSeq. (2023). NCBI Reference Sequence Database. URL: https://www.ncbi.nlm.nih.govrefseq. Accessed 18 May 2023.

Rehfeld JF. (2017, Apr 13). Cholecystokinin-From Local Gut Hormone to Ubiquitous Messenger. Front Endocrinol (Lausanne). 8: 47. https://doi.org/10.3389/fendo.2017.00047; PMid:28450850 PMCid:PMC5389988

Rehfeld JF. (2021, Mar). Cholecystokinin and the hormone concept. Endocr Connect. 10 (3): R139-R150. https://doi.org/10.1530/EC-21-0025; PMid:33640870 PMCid:PMC8052576

Rehfeld JF. (2021, Sep 17). Cholecystokinin and Panic Disorder: Reflections on the History and Some Unsolved Questions. Molecules. 26 (18): 5657. https://doi.org/10.3390/molecules26185657; PMid:34577128 PMCid:PMC8469898

Richards S, Aziz N, Bale S et al. (2015, May). ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 17 (5): 405-424. https://doi.org/10.1038/gim.2015.30; PMid:25741868 PMCid:PMC4544753

Steinert RE, Feinle-Bisset C, Asarian L et al. (2017, Jan). Ghrelin, CCK, GLP-1, and PYY (3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. Physiol Rev. 97 (1): 411-463. Erratum in: Physiol Rev. 2017 Jul 1; 97 (3): 1229. https://doi.org/10.1152/physrev.00031.2014; PMid:28003328 PMCid:PMC6151490

Zhou L, Yang H, Lin X et al. (2012). Cholecystokinin elevates mouse plasma lipids. PLoS One. 7 (12): e51011. https://doi.org/10.1371/journal.pone.0051011; PMid:23300532 PMCid:PMC3533889

Zhou L, Yang H, Okoro EU et al. (2014, May 9). Up-regulation of cholesterol absorption is a mechanism for cholecystokinin-induced hypercholesterolemia. J Biol Chem. 289 (19): 12989-12999. https://doi.org/10.1074/jbc.M113.534388; PMid:24692543 PMCid:PMC4036314

Downloads

Published

2023-09-28

Issue

Section

Original articles